Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy (technically a misnomer), benign enlargement of the prostate (BEP), and adenofibromyomatous hyperplasia, refers to the increase in size of the prostate.

Properly, BPH involves hyperplasia rather than hypertrophy, but the nomenclature is often interchangeable, even amongst urologists. It involves hyperplasia of prostatic stromal and epithelial cells, resulting in the formation of large, fairly discrete nodules in the periurethral region of the prostate. When sufficiently large, the nodules compress the urethral canal to cause partial, or sometimes virtually complete, obstruction of the urethra, which interferes with the normal flow of urine. It leads to symptoms of urinary hesitancy, frequent urination, dysuria (painful urination), increased risk of urinary tract infections, and urinary retention. Although prostate specific antigen levels may be elevated in these patients because of increased organ volume and inflammation due to urinary tract infections, BPH is not considered to be a premalignant lesion.

Adenomatous prostatic growth is believed to begin at approximately age 30 years. An estimated 50% of men have histologic evidence of BPH by age 50 years and 75% by age 80 years. In 40-50% of these patients, BPH becomes clinically significant.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Plant compounds give '1-2' punch to colon cancer

The combination of two plant compounds that have medicinal properties - curcumin and silymarin - holds promise in treating colon cancer, according Saint Louis University research published in the June 23 issue of the Journal ...

For whom the births (and worms) toll

Human childbirth is not only unpleasant, it's also assumed to take a toll on women's health, even while women have a greater life expectancy. A new study led by UC Santa Barbara researchers, however, finds that indigenous ...

Chinese team to pioneer first human CRISPR trial

(Medical Xpress)—A team of researchers at Sichuan University's West China Hospital has announced plans to begin a clinical trial where cells modified using the CRISPR gene editing technique will be used on human beings ...